Core B: Biospecimen Repository and Processing Core

核心 B：生物样本存储库和处理核心

基本信息

批准号：
10261400
负责人：
Begonya Comin-Anduix
金额：
$ 34.96万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-11 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10261400
关键词：
Ambulatory Care Facilities Animals Antibodies BRAF gene Biocompatible Materials Biological Specimen Banks Biological Specimen database Biology Biopsy Cell Line Cells Chromium Clinical Data Combined Modality Therapy Computer software Cryopreservation Cytometry Development Enrollment Ensure Fine needle aspiration biopsy Fluorescence Generations Health Insurance Portability and Accountability Act High-Throughput Nucleotide Sequencing Histology Human Human Resources Immune Immune checkpoint inhibitor Immunofluorescence Immunologic Immunohistochemistry Immunotherapy In Situ Label Laboratories Location MEKs Melanoma Cell Metastatic Melanoma Minority Molecular Online Systems Paraffin Embedding Pathologic Pathology Patients Performance Phenotype Preparation Procedures Process Quality Control Reagent Research Research Personnel Resistance Sampling Scanning Services Slide Stains Standardization Suspensions System T cell receptor repertoire sequencing Techniques Technology Tissue Embedding Tissues Validation Work biobank clinically relevant combinatorial design digital established cell line high throughput analysis histological image inhibitor/antagonist laser capture microdissection melanoma prevent prospective repository response single cell analysis single-cell RNA sequencing success targeted treatment therapeutic evaluation treatment response tumor tumor microenvironment

项目摘要

CORE B ABSTRACT Recent advances in the treatment of metastatic melanoma with targeted therapies are highly successful initially but are ultimately limited by the development of tumor resistance. On the other hand, checkpoint inhibitors are associated with durable responses but only benefit a minority of patients. The aims of all of the projects in this application are to understand the mechanisms and develop strategies to overcome resistance to both combined targeted therapies and checkpoint inhibitor immunotherapies in melanoma. The proposed studies require an efficient Biospecimen Core that can provide a variety of high quality biospecimens to the investigators. The specific aims of the Biospecimen Repository and Processing Core (BRPC - Core B) of the PPG are to: 1 ) Centralize performance of specialized pathology services, including biosample (tissue and biofluid) storage, tracking, distribution and analysis; 2) Provide well-characterized melanoma tissues, cell lines and short-term cultures from patients enrolled on combination therapies and treated with BRAF/MEK inhibitors or checkpoint inhibitors and prospectively develop additional cell lines; and 3) Develop techniques to better characterize cells from within the tumor microenvironment for more sophisticated analysis in situ and at the single cell level. BRPC provide the advanced expertise in melanoma biology, cell line development, pathologic interpretation and biorepository management that is required by all proposed studies.

核心B摘要靶向疗法的转移性黑色素瘤治疗的最新进展最初是非常成功的但最终受到肿瘤耐药性的发展而受到限制。另一方面，检查点抑制剂是与持久反应有关，但仅受益于少数患者。所有项目的目的应用是要了解机制并制定策略以克服对两者的抗药性靶向疗法和检查点抑制剂免疫疗法在黑色素瘤中。拟议的研究需要有效的生物晶体核心可以为研究人员提供各种高质量的生物测量。这 PPG的生物测量存储库和加工核心（BRPC -Core B）的具体目的是：1）集中化专业病理服务的性能，包括生物样品（组织和生物流体）存储，跟踪，分布和分析； 2）提供良好的特征性黑色素瘤组织，细胞系和短期接受组合疗法并接受BRAF/MEK抑制剂或检查点治疗的患者的培养物抑制剂并前瞻性开发其他细胞系； 3）开发技术以更好地表征细胞从肿瘤微环境内，以进行原位和单细胞水平进行更复杂的分析。 BRPC 提供黑色素瘤生物学，细胞系发育，病理解释和的高级专业知识所有拟议的研究都要求的生物座管理管理。